Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

Core Insights - Paratek Pharmaceuticals is presenting new clinical data for NUZYRA (omadacycline) at IDWeek 2025 and CHEST 2025, focusing on its efficacy against community-acquired infections and nontuberculous mycobacterial pulmonary disease [1][2] Group 1: Clinical Data Presentations - The upcoming presentations will highlight NUZYRA's potential utility against serious community-acquired infections, including quality-of-life outcomes from the Phase 3b OPTIC-2 study and microbiological results from a Phase 2 study on NTM-PD [2][5] - An oral presentation at CHEST will report on health-related quality-of-life outcomes from the OPTIC-2 trial, while IDWeek will feature microbiological outcomes from the NTM-PD study [3][5] Group 2: Study Details - The CHEST 2025 oral presentation will take place on October 21, focusing on a randomized, controlled Phase 3b trial comparing omadacycline to moxifloxacin in community-acquired bacterial pneumonia [3] - A poster session at CHEST will present pooled efficacy and safety data from the Phase 3 OPTIC and OPTIC-2 trials [4] - IDWeek will include a presentation on microbiological outcomes from a Phase 2 trial of omadacycline in adults with NTM-PD [5] Group 3: Company Overview - Paratek Pharmaceuticals is a privately held company focused on developing specialty therapies for public health threats and unmet medical needs, with NUZYRA indicated for community-acquired bacterial pneumonia and acute bacterial skin infections [7][10] - The company was acquired in 2023 by B-FLEXION and Novo Holdings, indicating a strategic move to diversify its portfolio [7]